News & Updates
Filter by Specialty:

New COVID-19 campaign highlights speed in testing, treating
The Malaysian Society of Infection Control and Infectious Diseases (MyICID) in collaboration with Family Medicine Association Malaysia (FMSA) and Malaysian Medical Association (MMA) have launched an educational campaign themed ‘COVID-19: Quickly test and treat.’
New COVID-19 campaign highlights speed in testing, treating
05 Mar 2023
SGLT-2I–MRA combo yields maximal kidney, cardiovascular protection in T2DM, CKD
Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.
SGLT-2I–MRA combo yields maximal kidney, cardiovascular protection in T2DM, CKD
05 Mar 2023
Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.
Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
03 Mar 2023
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.





